An amendment to Poland's tax code, effective from December 1, could eliminate a barrier to the development of the clinical research market in the east European country. A report by analyst firm Polish Market Research said the change to Article 27 of the Goods and Services Tax Act involves making the list of "expert services" compiled under the legislation more explicit to ensure that clinical research is taxed in the client's country, rather than Poland.
The situation in Poland has been confusing for potential contractors, with four separate categories under which contract research organizations operate, some of which are GS tax exempt. To make matters worse, individual tax inspectors allegedly have extensive latitude to determine which category a specific case will be treated as.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze